Kane Biotech Inc.
KNE
Rank in Stocks
#30676
Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm... Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.
Share Price
$0.02097257
Last synced: 2026-11-18
Market Cap
$4.30M
Change (1 day)
-0.05%
Change (1 year)
-1.40%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Kane Biotech Inc. (KNE)
Category
Healthcare
Operating Margin for Kane Biotech Inc. (KNE)
Operating Margin as of November 2026 TTM: -8,113.83%
According to Kane Biotech Inc.'s latest financial reports, its current operating margin (TTM) is -8,113.83%. At the end of 2025 the company had an operating margin of -727.40%.
Operating Margin history for Kane Biotech Inc. from 2003 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -8,113.83% | 1,015.46% |
| 2025 | -727.40% | 236.82% |
| 2024 | -215.96% | -90.42% |
| 2023 | -2,253.58% | 2.15% |
| 2022 | -2,206.05% | 626.27% |
| 2021 | -303.75% | -3.53% |
| 2020 | -314.88% | 48.53% |
| 2019 | -212.00% | -66.24% |
| 2018 | -627.89% | 141.21% |
| 2017 | -260.31% | -73.83% |
| 2016 | -994.67% | -35.46% |
| 2015 | -1,541.11% | -57.60% |
| 2014 | -3,634.89% | 300.78% |
| 2013 | -906.95% | 0.00% |
| 2012 | 0.00% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | -100.00% |
| 2007 | -6,033.56% | 67.41% |
| 2006 | -3,603.98% | 0.00% |
| 2005 | 0.00% | -100.00% |
| 2004 | -4,492.04% | 748.92% |
| 2003 | -529.15% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.87% | -100.00% |
US
|
|
| -116.04% | -99.99% |
US
|
|
| 25.57% | -100.00% |
AU
|
|
| 29.35% | -100.00% |
NL
|
|
| 31.23% | -100.00% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Kane Biotech Inc.'s operating margin
What is Kane Biotech Inc.'s operating margin?
Kane Biotech Inc.'s operating margin is -8,113.83%, as of Nov 2026.
What was Kane Biotech Inc.'s operating margin in 2025?
In 2025, Kane Biotech Inc.'s operating margin was -727.40%, compared with -215.96% in 2024.
How has Kane Biotech Inc.'s operating margin changed since 2020?
From 2020 to 2025, Kane Biotech Inc.'s operating margin was highest in 2024 (-215.96%) and lowest in 2023 (-2,253.58%).
How does Kane Biotech Inc.'s operating margin compare with similar companies?
Kane Biotech Inc.'s operating margin (-8,113.83%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.